Why Crinetics Stock Doubled After Vertex’s $10 Billion Buyout

The post Boom Times For Autoimmune Disease Therapies appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at the boom in autoimmune disease therapies, OpenAI’s healthcare push, Vertex’s $10 billion purchase of Crinetics, and more. To get it in your inbox, subscribe here. AbbVie’s Skyrizi is on track to become the world’s second-highest selling drug, according to pharma consultants Evaluate. The Associated Press AbbVie’s Skyrizi, an injectable drug for autoimmune diseases that include psoriasis and Crohn’s disease, is expected to surpass $33 billion in revenue in 2032, making it the world’s second-biggest selling drug, according to a recent report from pharma data and consulting firm Evaluate. That puts it smack between Eli Lilly’s GLP-1 blockbusters, Mounjaro (for diabetes) and Zepbound (for weight loss). “Only autoimmune disease drugs come close to rivaling Lilly’s anti-obesity blockbusters given their potential to treat dozens of conditions driven by s

The post Bitcoin Mining M&A Heats Up After Vertex’s $10 Billion Biotech Buyout appeared on BitcoinEthereumNews.com. Crypto News Vertex Pharmaceuticals agreed to acquire Crinetics Pharmaceuticals for $10 billion in cash on Monday, July 6, sending the smaller drugmaker’s stock to a fresh all-time high as shares nearly doubled in a single session. Vertex will pay $85 per share, roughly twice Crinetics’ closing price the day before the announcement. The premium underscores how aggressively large-cap acquirers are chasing late-stage assets, a dynamic now spilling from biotech into digital-asset infrastructure. Our reading of the tape shows the deal instantly reset how the market values Crinetics, with the stock detaching from its own fundamentals and gravitating toward the agreed takeout price rather than its standalone growth outlook. What Vertex is actually buying is Palsonify, a once-daily pill for acromegaly — a rare disorder driven by excess growth hormone that patients previously mana

The post VRTX Elliott Wave forecast: Next bullish target at $556.9 – $646.4 appeared on BitcoinEthereumNews.com. Vertex Pharmaceuticals Incorporated (VRTX), operates as Biotechnology company in the United States, Europe & internationally. It offers transformative medicines for people with serious diseases of different age groups. It comes under Healthcare – Biotech sector & trades as “VRTX” ticker at Nasdaq. In weekly, VRTX confirmed higher high above November-2024 high expected in last article. It should continue rally towards 556.9 – 591 area in shorter cycle within May-2026 sequence. We like to buy the pullback in 3, 7 or 11 swings at extreme area, when reach. VRTX – Elliott Wave latest weekly view In weekly, it placed ((I)) at $306.08 high (July-2020) & ((II)) at $176.36 low (October-2021). Above there, it ended (I) of ((III)) at $519.88 high (November-2024) & (II) at $362.50 low (August-2025). Within (I), it ended I at $292.75 high, II at $233.01 low, III at $510.63 high, IV at $4